Shinome Brief · 2026-07-21

AI & Tech

6 stories

The lead

Washington moves to restrict Chinese open-weight AI models

Policy experts note an outright ban on downloadable open weights is close to unenforceable and raises First Amendment issues. The practical fight is over government procurement and whether US firms can keep using Chinese models in production.

After Moonshot's Kimi K3 launch, the Trump administration is reviving a push to bar Chinese open-weight models, with federal procurement bans seen as the most viable route. Treasury's Bessent says US watermarks are turning up in Chinese models via distillation and floated sanctions, with US-China AI talks set for September.

CNBC

KRALYSWatch this before standardizing any open model in the Katarina stack: procurement rules could force a swap, so keep the AI layer model-agnostic rather than wired to one provider.

1
Head of US AI safety agency resigns after three months
Chris Fall, director of the Center for AI Standards and Innovation (the renamed US AI Safety Institute), stepped down with no reason given. An interim lead from the Commerce Department takes over as the agency pivots from safety toward standards and innovation.
CNBC
CONVOA useful signal in senior conversations: US AI governance is in flux right when it is picking fights over Chinese models, so expect policy, not just tech, to move the market.
2
Alibaba releases Qwen-Image-3.0
Qwen ships a new open image-generation model pitched on richer text rendering, more authentic detail and stronger world knowledge in prompts.
Qwen
SHINOMETest it for Shinome marketing assets and client-facing graphics: an open image model that renders text well can replace paid design tools for social posts at zero cost.
3
Nativ lets you run frontier open models locally on a Mac
A new open tool packages local inference for frontier open-weight models on Apple Silicon, keeping prompts and data on-device.
Simon Willison
KRALYSFor Kralys, this is the privacy answer to the model fight: run analysis on deal or client documents locally so nothing sensitive leaves the machine, no cloud provider involved.
4
Sony sues Udio over roughly 30,000 songs used to train its AI music generator
Sony Music has published the list of around 30,000 tracks it says Udio used without a license, escalating the copyright fight over AI-generated music.
The Verge
SHINOMENote for Shinome content: AI-generated music sits in live litigation, so keep reels on licensed or platform-native audio rather than AI tracks that could be pulled.
5
Open models are now good enough to audit real production code
A developer reports that an open model flagged five real bugs in a post-quantum cryptography project that frontier models had missed, a concrete data point on how far open-weight code review has come.
r/LocalLLaMA
KRALYSTry pointing an open model at the coach app and client PWA codebase for a security and bug pass: it costs nothing to run and catches things a single reviewer misses.

Finance & Markets

7 stories

The lead

Trump imposes 50% tariffs on a range of Canadian goods

Ottawa called it a violation of the USMCA and both sides pointed to the 30-day window for talks. The measured market reaction suggests investors are pricing negotiation, not a full trade war, for now.

Trump signed proclamations putting 50% tariffs on Canadian autos, dairy and alcohol, covering roughly $20bn of annual imports, citing trade discrimination. The duties carry a 30-day window before taking effect and markets read them as a negotiating tactic, with the Canadian dollar slipping but not cratering.

CNBC

CONVOA live example for senior conversations of tariff headlines that move currencies more than equities: the 30-day delay is the tell that this is leverage, not a done deal.

1
Jamie Dimon says he would not buy stocks or Treasurys at current prices
The JPMorgan CEO said markets are underestimating risks and that he sees little value at today's levels in either equities or US government bonds.
CNBC
CONVOA clean contrarian line to drop with senior finance people: the biggest US bank CEO is publicly refusing to buy stocks or Treasurys here, which reframes any bullish pitch.
2
Biotech M&A hits a record as Big Pharma races to refill pipelines
First-half biotech dealmaking reached about $134bn, past all of last year, with 33 deals worth $1bn or more and full-year value potentially topping $250bn. Patent cliffs and buoyant markets are driving a FOMO-style buying wave, mostly bolt-ons in the $1bn to $5bn range.
Financial Times
KRALYSDeal-logic ammo for Kralys: the money is chasing $1bn to $5bn bolt-ons, so any healthcare angle should be framed as a tuck-in that plugs a specific pipeline gap, not a moonshot.
3
Novo Nordisk sues Eli Lilly over weight-loss drug advertising
Novo Nordisk is suing Eli Lilly over what it calls deliberately false GLP-1 comparison ads, as the two dominant players fight over an obesity-drug market that both frame as hitting an inflection point.
Financial Times
CONVOTies straight to today's fitness lead: the GLP-1 duopoly is now litigating each other, a sign the market is maturing and the next fight is share, not science.
4
Stadler Rail refuses to pay a CHF 10m ransom after a cyberattack
Swiss train maker Stadler Rail confirmed a cyberattack and said it will not pay the roughly CHF 10m ransom demanded, joining a growing set of firms publicly declining to pay.
Le Temps
KRALYSConcrete Swiss reference point for any ops or risk discussion at Kralys: a major local manufacturer is publicly choosing not to pay, which is the emerging playbook worth mirroring.
5
Swatch Group targets faster growth and a rebound in profitability
The Swiss watchmaker signaled accelerating growth and set out plans for a recovery in margins after a soft stretch for the luxury sector.
Le Temps
CONVOA local read for Swiss conversations: Swatch guiding to a margin rebound is a small but real tell on whether luxury demand is turning, useful when the room assumes it is still falling.
6
GM beats earnings and raises guidance on a resilient consumer
General Motors topped estimates and lifted its outlook, citing steady consumer demand and firm pricing even as it leans back toward gas-powered models.
CNBC
CONVOCounterweight to the Dimon warning in the same conversation: GM raising guidance on pricing power says the US consumer is not rolling over yet, which is the more nuanced take.

Fitness & Performance

5 stories

The lead

People on GLP-1 drugs tend to move less, right when they most need to protect muscle

With obesity drugs now mainstream, the coaching opportunity is muscle retention, not more weight loss. The protocol is simple and evidence-backed: resistance train and hit a protein floor while the drug does the appetite work.

Research presented at ENDO 2026 finds physical activity often drops among people taking GLP-1 medications, even though a meaningful share of the weight they lose is lean mass. Trials like S-LITE show supervised resistance training plus about 1.2 to 1.6 g/kg of protein a day can preserve or even add lean mass during treatment.

Endocrine Society

SHINOMEBuild a Shinome offer around this: a resistance-plus-protein protocol for clients on GLP-1 who want to keep muscle, a clearly defined niche with a growing customer base.

1
New data: GLP-1 weight loss may not cost as much muscle as feared
A 2026 study in mice and humans reports that weight loss on GLP-1 medicines does not produce a disproportionate loss of muscle mass or function, tempering some of the muscle-wasting alarm around the drugs.
Cell Reports Medicine
CONVOThe honest nuance to give clients: GLP-1 muscle loss is real but roughly proportional, so the fix is protein and lifting, not fear, which is a more credible pitch than scaremongering.
2
Harvard study finds a strength-training sweet spot for a longer life
A 30-year study of about 147,000 adults found that 90 to 119 minutes of weekly strength training was linked to a 13% lower all-cause mortality, with benefits plateauing near 120 minutes and combining lifting with cardio pushing risk reduction to around 40%.
Harvard T.H. Chan School of Public Health
SHINOMEA powerful client hook for Shinome: the longevity payoff maxes out around two hours of lifting a week, so sell consistency at a realistic dose rather than punishing volume.
3
Venture funding for consumer fitness has cooled
Crunchbase reports that venture capital has pulled back from consumer fitness startups, with investors more cautious on apps and hardware after a funding boom, and money rotating toward longevity and preventive-health plays.
Crunchbase News
SHINOMEReinforces the Shinome path: do not build the business around raising, fund it from coaching revenue, since the VC door for consumer fitness is mostly shut right now.
4
Renaissance Periodization weighs whether a new resistance technology could replace free weights
The RP team examines an emerging resistance technology and whether it can match or replace traditional free weights for building muscle and strength.
Renaissance Periodization
SHINOMEWorth a watch for the coach app roadmap: if adaptive resistance tech is maturing, decide early whether Shinome programming should support it or stay barbell-first.